1.gif (1892 bytes)                      

Correspondence

Indian Pediatrics 2007; 44:792-793

Rabies Vaccine: A Case for Optional Childhood Vaccination


Asia accounts for approximately 90% of all rabies fatalities(1). WHO surveys reveal that half of deaths occur in children and only one third of them receive post exposure treatment (PET) majority being males. Many of these exposures are never reported as a child may be alone with the dog/may not impart significance to few abrasions/may be scared of some painful injections following dog bite and not report it to his caretakers deliberately. Children are more vunerable to get dog bites as they tend to play with/tease them frequently and can be easily overpowered by dogs. Incubation period also tends to be shorter due to their lesser body surface area and frequent bites on head and neck because of small physique.

The present WHO guidelines include immediate rabies immunoglobulin (RIG) administration along with vaccine to all the class III bites. However, importance of RIG is not known to most of the treating personnel which is being administered only in 2.1% of the cases, a factor which is responsible for majority of rabies deaths despite receiving cell culture vaccines in time(2). Failure to use RIG amounts to deficient medical services and consequently, if patient develops rabies, the physician is liable to be sued for compensation(3). Further, HRIG is not available freely. The lack of awareness compounded with its non-availability leaves the next option i.e., administration of ERIG (Equine Rabies Immunoglobulin) which requires doubling of the dose and has inherent risks of frequent hypersensitivity reactions. In the latter situation WHO recommends double dose of cell culture vaccine at two different sites while hoping for an immune response to occur before the killer virus reaches the brain.

The immune responses to post exposure vaccination by even the best modern vaccines are regularly seen by the 14th day (protective titer of >0.5 IU/mL) and this response may occur later than the incubation period. On the other hand pre-exposure vaccination generates memory cells which persist for life and on giving booster doses on 0, 3 days of the bite antibodies are produced rapidly within a short span of 1-2 days.

Future does not hold brighter prospects as dogs which happen to be the major agents of transmission are rapidly increasing in number in India (18.8 million in 1987 and now 25 million)(4). Further, non-availability of RIG is also predicted because of ban being imposed on use of horses for serum production.

Therefore, considering the overall scenario we suggest that the rabies vaccine should be incorporated in the IAP schedule in the category of additional/optional vaccines for pre-exposure prophylaxis. The efficacy of this vaccine in preventing rabies deaths in children should definitely place it before the chicken pox vaccine which seems to be more of manufacturers priority where the prevention is mainly in terms of few working/school days lost because of illness. IAP has incorporated antirabies vaccine in the list of recommended vaccines, however, it has not placed it at its right place(5). A vaccine which prevents deaths should be offered as pre-exposure prophylaxis to all those children whose daily activity involves an environment prone to rabid animal bites.

Rekha Harish,
Department of Pediatrics,
Govt. Medical College,
Jammu 180 004,
J & K, India.
E-mail: [email protected]  

References

1. Rabies Vaccines, WHO position paper. Wkly Epidemiol Rec 2002; 77: 109-120.

2. Assessing Burden of Rabies in India: Rabies Survey 2003. Association for Prevention and Control of Rabies in India (APCRI). From www.apcri.org Accessed on 4. 07. 2007.

3. Anti Rabies Immunization. From: http://www.apcri.org/antirabies.immunization.htm. Accessed on 21.08.2006.

4. Dutta A K. Pediatric rabies: Association for Prevention and Control of Rabies in India. APCRI J 2002; 8: 36-40.

5. IAP Guidebook on Immunization. Available from: http://iapindia.org/nonuip.cfm. Accessed on 1.12.2006.

Home

Past Issue

About IP

About IAP

Feedback

Links

 Author Info.

  Subscription